In particular, the upregulation of DHEA in gliomas is caused by Sp1-mediated cytochrome P450 (CYP) 17A1 overexpression [7], implying that CYP17A1 is a potential target for glioma treatment. The gene discussed is CYP17A1; the disease is central nervous system cancer.